Crystal / Obstructive Nephropathy
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ overall reversibility
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Real-world reporting for this lesion
FAERS across all lesions →How disproportionately crystal / obstructive nephropathy is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.
Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.
Documented in a profile with no reporting signal. 33 of 36 sit on a reportable term with enough reports, so FAERS could have flagged the lesion and did not; the rest are expected silences.
A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.
The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.
- RelacorilantSelective glucocorticoid-receptor antagonist · FAERS only11.16 (3.54–35.21) · n=3 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- CabazitaxelTaxane · FAERS only9.28 (7.52–11.46) · n=89 * Reporting signal, on terms consistent with the lesion rather than naming it.
- NaxitamabAnti-GD2 antibody · FAERS only7.29 (3.01–17.66) · n=5 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- OctreotideSomatostatin analog · FAERS only5.60 (5.11–6.13) · n=475 * Reporting signal, on terms consistent with the lesion rather than naming it.
- EpcoritamabBispecific (CD20×CD3)4.73 (3.54–6.33) · n=46 * Reporting signal, on terms consistent with the lesion rather than naming it.
- VandetanibVEGFR/EGFR/RET TKI · FAERS only4.52 (2.72–7.52) · n=15 * Reporting signal, on terms consistent with the lesion rather than naming it.
- PamidronateBisphosphonate · FAERS only3.97 (2.96–5.33) · n=45 * Reporting signal, on terms consistent with the lesion rather than naming it.
- SelumetinibMEK inhibitor · FAERS only3.86 (2.42–6.14) · n=18 * Reporting signal, on terms consistent with the lesion rather than naming it.
- AcalabrutinibBTK inhibitor3.74 (3.15–4.45) · n=132 * Reporting signal, on terms consistent with the lesion rather than naming it.
- LanreotideSomatostatin analog · FAERS only3.63 (2.91–4.53) · n=80 * Reporting signal, on terms consistent with the lesion rather than naming it.
- BicalutamideNonsteroidal antiandrogen · FAERS only3.54 (3.01–4.16) · n=150 * Reporting signal, on terms consistent with the lesion rather than naming it.
- PexidartinibCSF1R inhibitor · FAERS only3.52 (1.67–7.41) · n=7 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- CladribinePurine analog2.67 (2.13–3.36) · n=74 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Methotrexate (high-dose)Antifolate1.97 (1.90–2.05) · n=2,645 * Reporting signal, on terms consistent with the lesion rather than naming it.
- RituximabAnti-CD20 antibody1.69 (1.59–1.80) · n=1,022 * Reporting signal, on terms consistent with the lesion rather than naming it.
- ZanubrutinibBTK inhibitor1.67 (1.08–2.60) · n=20 * Reporting signal, on terms consistent with the lesion rather than naming it.
- HydroxyureaRibonucleotide reductase inhibitor1.56 (1.27–1.92) · n=93 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Polatuzumab vedotinAntibody-drug conjugate (CD79b/MMAE)1.44 (1.06–1.96) · n=41 * Reporting signal, on terms consistent with the lesion rather than naming it.
- BendamustineAlkylator1.38 (1.13–1.70) · n=93 * Reporting signal, on terms consistent with the lesion rather than naming it.
- RaltitrexedAntifolate (TS inhibitor)1.72 (0.55–5.34) · n=3 No reporting signal.
- PirtobrutinibNon-covalent BTK inhibitor1.57 (0.59–4.19) · n=4 No reporting signal.
- GlofitamabBispecific (CD20×CD3)1.46 (0.81–2.63) · n=11 No reporting signal.
- MosunetuzumabBispecific (CD20×CD3)1.29 (0.48–3.46) · n=4 No reporting signal.
- Dactinomycin (actinomycin D)Antitumor antibiotic1.13 (0.54–2.38) · n=7 No reporting signal.
- ObinutuzumabAnti-CD20 antibody1.02 (0.76–1.35) · n=47 No reporting signal.
- Gemtuzumab ozogamicinAntibody-drug conjugate (CD33/calicheamicin)0.98 (0.53–1.82) · n=10 No reporting signal.
- DecitabineHypomethylating agent0.94 (0.56–1.59) · n=14 No reporting signal.
- VenetoclaxBCL-2 inhibitor0.88 (0.75–1.03) · n=154 No reporting signal.
- CytarabineNucleoside analog0.83 (0.70–0.97) · n=146 No reporting signal.
- MitoxantroneAnthracenedione0.74 (0.43–1.27) · n=13 No reporting signal.
- AmsacrineTopoisomerase II inhibitor (acridine)0.71 (0.10–5.07) · n=1 No reporting signal.
- Inotuzumab ozogamicinAntibody-drug conjugate (CD22/calicheamicin)0.60 (0.25–1.44) · n=5 No reporting signal.
- EtoposideTopoisomerase II inhibitor0.59 (0.49–0.70) · n=123 No reporting signal.
- FludarabinePurine analog0.56 (0.44–0.72) · n=63 No reporting signal.
- Ibritumomab tiuxetanRadioimmunotherapy (Y-90 anti-CD20)0.47 (0.12–1.88) · n=2 No reporting signal.
- Brentuximab vedotinAntibody-drug conjugate (CD30/MMAE)0.45 (0.26–0.77) · n=13 No reporting signal.
- ThalidomideImmunomodulatory drug (IMiD)0.44 (0.29–0.67) · n=23 No reporting signal.
- Lisocabtagene maraleucelCD19 CAR-T cell therapy0.41 (0.06–2.90) · n=1 No reporting signal.
- PomalidomideImmunomodulatory drug (IMiD)0.34 (0.28–0.41) · n=99 No reporting signal.
- ElranatamabBispecific (BCMA×CD3)0.32 (0.08–1.28) · n=2 No reporting signal.
- MechlorethamineAlkylating agent (nitrogen mustard)0.32 (0.08–1.27) · n=2 No reporting signal.
- IdarubicinAnthracycline0.31 (0.04–2.19) · n=1 No reporting signal.
- Idecabtagene vicleucelBCMA CAR-T cell therapy0.29 (0.04–2.05) · n=1 No reporting signal.
- BlinatumomabBiTE (CD19×CD3)0.13 (0.05–0.35) · n=4 No reporting signal.
- Ciltacabtagene autoleucelBCMA CAR-T cell therapy0.11 (0.03–0.43) · n=2 No reporting signal.
reporting odds ratio (log) — no signal left of the dashed line at 1.0
No ratio — no XTAL reports, or too few (count in brackets): Clofarabine, Infigratinib, Linvoseltamab, Lurbinectedin, Nelarabine, Pralatrexate, Revumenib
No ratio — under 50 FAERS reports in total: Odronextamab, Pivekimab sunirine, Sonrotoclax
All 45 agents documented with XTAL in the atlas are shown whether or not FAERS flags them, plus the 39 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (CAR-T cell therapy) are not asked of FAERS; their member agents are ranked individually. 48 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.
Management approach
Full framework →Prevent precipitation; for established high-dose methotrexate toxicity, glucarpidase rapidly cleaves circulating drug.
Drug-level levers
- Hold further methotrexate until clearance and renal recovery.
- For tumor-lysis urate nephropathy, prophylaxis is the key lever.
Pharmacologic toolkit
- Hydration + urinary alkalinization — Vigorous IV hydration and urine alkalinization keep methotrexate soluble.
- Leucovorin rescue — High-dose leucovorin guided by serial methotrexate levels.
- Glucarpidase — For delayed methotrexate clearance / AKI: recombinant carboxypeptidase-G2 cleaves plasma methotrexate, usually allowing recovery without dialysis.
- Rasburicase (tumor lysis) — For urate crystal nephropathy from tumor lysis, with hydration; also manage hyperphosphatemia.
When to biopsy
Not indicated — the diagnosis is clinical and biochemical (drug levels, uric acid, urine crystals).
Monitoring
- · Serial methotrexate levels, creatinine, urine pH
- · Uric acid, phosphate, potassium (tumor lysis)
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
What the guidelines say
All guidelines →Society and consensus recommendations that speak to crystal / obstructive nephropathy.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
Cited incidence across agents
Where the literature gives a representative crystal / obstructive nephropathy figure, the agents ranked highest first. Hover a dot for its cited note.
Offending agents
Signature offenders
18Agents for which crystal / obstructive nephropathy is the defining renal lesion.
Also associated
28Agents that cause crystal / obstructive nephropathy as a secondary pattern alongside a different signature lesion.